BiotechTube

AZD5069 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchiectasis

Conditions

Bronchiectasis, Lung Disease, Respiratory Diseases

Trial Timeline

Feb 1, 2011 → Feb 1, 2012

NCT ID
NCT01255592

About AZD5069 + Placebo

AZD5069 + Placebo is a phase 2 stage product being developed by AstraZeneca for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01255592. Target conditions include Bronchiectasis, Lung Disease, Respiratory Diseases.

What happened to similar drugs?

1 of 10 similar drugs in Bronchiectasis were approved

Approved (1) Terminated (2) Active (8)
✅Aztreonam lysineGilead SciencesApproved
❌Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
🔄Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
🔄Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT01704495Phase 2Completed
NCT01255592Phase 2Completed
NCT01100047Phase 1Completed
NCT01051505Phase 1Completed
NCT00953888Phase 1Completed

Competing Products

20 competing products in Bronchiectasis

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
32
AZD9668 + PlaceboAstraZenecaPhase 2
35
AZD0292AstraZenecaPhase 2
42
TIP + TIP and placebo + PlaceboNovartisPhase 2
35
Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
40
Placebo to Ciprofloxacin DPI (BAYQ3939)NovartisPre-clinical
26
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
40
QBW251 + PlaceboNovartisPhase 2
27
Ciprofloxacin (Cipro, BAYQ3939) + PlaceboNovartisPhase 2
35
AZLI + PlaceboGilead SciencesPhase 3
40
Aztreonam lysineGilead SciencesApproved
35
AZLIGilead SciencesPhase 2
35
AZLI + PlaceboGilead SciencesPhase 3
40
Itepekimab (SAR440340) + PlaceboSanofiPhase 2
35
CSL787 + PlaceboCSLPhase 1
29
CSL787 + PlaceboCSLPhase 2
42
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
47
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
35
Group A + Group BBayerPre-clinical
23
BAY85-8501 + PlaceboBayerPhase 2
32